4CPS-147 Evaluation of the effectiveness and safety of anti-CGRP antibodies in the treatment of migraine

<h3>Background and Importance</h3> Increased levels of calcitonin gene-related peptide (CGRP) in blood and cerebrospinal fluid during migraine episodes have prompted the development of anti-CGRP monoclonal antibodies(anti-CGRP-mAb) used for migraine prevention. <h3>Aim and Objectives</h3> To evaluate the use of anti-CGRP-mAb since their approval to determine effectiveness and safety in daily clinical practice. <h3>Material and Methods</h3> Retrospective observational study, including all patients treated with anti-CGRP-mAb from 2019 to 2024. Variables collected: sex, age, diagnosis, baseline number of migraine days per month and after 3 months with anti-CGRP-mAb, duration of treatment. Effectiveness was determined by the percentage of patients achieving &gt;50% reduction in migraine days per month, treatment persistence and retention rate at 3/6/12/24/36/48 months. Safety was assessed by the occurrence of adverse events(AEs). <h3>Results</h3> We included 188 patients on anti-CGRP-mAb treatment with a mean age of 49.0±12.4 years and 161 (85.6%) were women. Episodic migraine included 54 (28.7%) patients compared to 134 (71.3%) patients with chronic migraine. The 50% (94) of patients were initially treated with galcanezumab, 21.3% (40) with fremanezumab and 28.7% (54) with erenumab. In terms of effectiveness, the patients who obtained a &gt;50% reduction in migraine days per month were 74 (78.7%), 26 (65.0%) and 37 (68.5%) patients in the galcanezumab, fremanezumab and erenumab groups, respectively. Furthermore, the mean persistence and mean reduction of migraine episodes per month obtained are shown in table 1. In terms of safety, all AEs were mild and appeared in 17 (18.1%) patients with galcanezumab, 6 (15%) with fremanezumab and 11 (20.4%) with erenumab. <h3>Conclusion and Relevance</h3> Galcanezumab was the most prescribed and produced the greatest reduction in migraine days per month. However, galcanezumab and erenumab had similar persistence and retention rates. In all cases, adverse effects were mild did not appear in more than 20% of patients. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest